REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
406.99
-0.61 (-0.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close407.60
Open407.74
Bid0.00 x 800
Ask0.00 x 1100
Day's Range404.40 - 409.65
52 Week Range281.89 - 442.00
Volume627,914
Avg. Volume742,036
Market Cap44.283B
Beta (3Y Monthly)0.93
PE Ratio (TTM)19.12
EPS (TTM)21.29
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est430.24
Trade prices are not sourced from all markets
  • Markit17 hours ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding REGN are favorable, with net inflows of $11.35 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
    Zacksyesterday

    Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

    Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

  • Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
    Zacks2 days ago

    Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

    Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

  • Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop
    Bloomberg2 days ago

    Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop

    The stock surged as much as 118 percent on Monday, the most ever, after data showed that its experimental therapy for atopic dermatitis, or eczema, demonstrated results that were better than Regeneron Pharmaceuticals and Sanofi’s star drug Dupixent. Regeneron shares fell 1 percent. Dupixent is forecast to generate $4.65 billion in sales by 2022, overtaking Eylea as the company’s largest drug, according to estimates compiled by Bloomberg.

  • GlobeNewswire4 days ago

    Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

    Praluent ® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease Approval is based on ODYSSEY OUTCOMES trial of 18,924 ...

  • Try These 3 Steps To Compound Your Profits In The Best Growth Stocks
    Investor's Business Daily4 days ago

    Try These 3 Steps To Compound Your Profits In The Best Growth Stocks

    If you use charts well, you can find the right time to buy the best growth stocks early in their run. After a breakout, look for places to add shares.

  • 10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run
    Zacks7 days ago

    10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run

    Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.

  • Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
    Zacks7 days ago

    Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

    Key highlights of the past week are regulatory and pipeline developments.

  • Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down
    Zacks7 days ago

    Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down

    Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.

  • PR Newswire7 days ago

    Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that four new sub-analyses from the Praluent® (alirocumab) ODYSSEY OUTCOMES cardiovascular (CV) outcomes trial will be presented at the American College of Cardiology's 68th Annual Scientific Session (ACC.19), held March 16-18, in New Orleans, LA. A Featured Clinical Research presentation that evaluates the impact of lowering lipoprotein(a) [Lp(a)] with Praluent on total CV events, independent of low-density lipoprotein cholesterol (LDL-C) reduction. An oral presentation that shows Praluent treatment was associated with larger reductions in the risk of major adverse CV events (MACE) and death in patients with polyvascular disease, compared to those without. Polyvascular disease is defined as having an acute coronary syndrome (ACS), plus either concurrent peripheral artery disease or cerebrovascular disease, or both.

  • Inovio Pharmaceuticals (INO) Q4 2018 Earnings Conference Call Transcript
    Motley Fool7 days ago

    Inovio Pharmaceuticals (INO) Q4 2018 Earnings Conference Call Transcript

    INO earnings call for the period ending December 31, 2018.

  • PR Newswire7 days ago

    Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science & the Public announced that Ana Humphrey, 18, of Alexandria, Virginia, won the top award in the Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. Forty finalists were honored tonight at the annual Regeneron Science Talent Search awards gala.

  • Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
    Zacks7 days ago

    Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

    The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

  • PR Newswire8 days ago

    FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., March 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.

  • Reuters8 days ago

    Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

    The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs. Shares of Regeneron closed up 2.3 percent at $412.05 on Monday. The FDA first approved the drug in 2017 and it has since been launched as a treatment for adults with moderate-to-severe atopic dermatitis, or eczema, as well as a drug for some asthma patients.

  • PR Newswire8 days ago

    FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

    CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.

  • Reuters8 days ago

    Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

    The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs. The drug was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.

  • Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
    Zacks9 days ago

    Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

    Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

  • PR Newswire9 days ago

    New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community

    Regeneron (NASDAQ: REGN) and UK Biobank announced today that a vast tranche of new human sequencing data is now available to health researchers, offering an unprecedented 'Big Data' resource to enhance understanding of human biology and aid in therapeutic discovery. The exome sequence data of 50,000 UK Biobank participants were generated at the Regeneron Genetics Center (RGC) through a collaboration between UK Biobank, Regeneron and GlaxoSmithKline (GSK) and are linked to detailed de-identified health records, imaging and other health-related data. Regeneron is also leading a consortium of biopharma companies (including Abbvie, Alnylam, AstraZeneca, Bristol-Myers Squibb, Biogen, Pfizer and Takeda) to complete exome sequencing of the remaining 450,000 UK Biobank participants by 2020.

  • Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?
    Investor's Business Daily11 days ago

    Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?

    On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.

  • PR Newswire11 days ago

    Regeneron Announces Upcoming Investor Conference Call

    TARRYTOWN, N.Y. , March 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: J.P. Morgan 2019 Spring Biotech Conference Call Series at ...

  • Regeneron (REGN) Up 0.8% Since Last Earnings Report: Can It Continue?
    Zacks12 days ago

    Regeneron (REGN) Up 0.8% Since Last Earnings Report: Can It Continue?

    Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.